These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

910 related items for PubMed ID: 7635795

  • 1. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, Scott W, Mailliard J, Lynch H, Bishop J.
    Int J Radiat Oncol Biol Phys; 1995 Jul 30; 32(5):1495-512. PubMed ID: 7635795
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
    Chin R, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, Hudspeth AS, Haponik EF.
    Am J Respir Crit Care Med; 1995 Dec 30; 152(6 Pt 1):2090-6. PubMed ID: 8520780
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 Dec 30; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2002 Jun 30; 29(6):797-803. PubMed ID: 12029554
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL, Fischman AJ.
    Chest; 2004 Sep 30; 126(3):755-60. PubMed ID: 15364753
    [Abstract] [Full Text] [Related]

  • 14. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.
    Eur J Cardiothorac Surg; 2009 Sep 30; 36(3):440-5. PubMed ID: 19464906
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
    Schmid RA, Hautmann H, Poellinger B, Kellner W, Moisseev A, Brinkbaeumer K, Weiss M, Hahn K, Dresel S.
    Nucl Med Commun; 2003 Jan 30; 24(1):37-45. PubMed ID: 12501018
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.